Varma T R, Patel R H, Rosenberg D
Int J Gynaecol Obstet. 1986 Feb;24(1):69-73. doi: 10.1016/0020-7292(86)90027-5.
Anti-thrombin III is the major inhibitor of activated blood clotting factors. We studied 320 patients with climacteric symptoms who received estrogen replacement therapy to assess the effect of hormone therapy on Anti-thrombin III (AT-III) activity). Of the 320 patients 80 patients received Prempak C (0.625 mg) for 2 years, 82 patients received Prempak C (1.25 mg) for 2 years, 78 patients received Cycloprogynova (1 mg) for 2 years and the remaining 80 patients received Cycloprogynova (2 mg) for 2 years. The mean AT-III activity before, during and 3 months after treatment showed no significant difference in all the four groups of patients. There was no incidence of myocardial infarction or stroke or thrombo-embolic disease in this group of 320 patients receiving estrogen replacement therapy.
抗凝血酶III是活化血液凝固因子的主要抑制剂。我们研究了320名有更年期症状且接受雌激素替代疗法的患者，以评估激素疗法对抗凝血酶III（AT-III）活性的影响。在这320名患者中，80名患者接受普美孕酮（0.625毫克）治疗2年，82名患者接受普美孕酮（1.25毫克）治疗2年，78名患者接受环丙孕酮炔雌醇片（1毫克）治疗2年，其余80名患者接受环丙孕酮炔雌醇片（2毫克）治疗2年。治疗前、治疗期间及治疗后3个月，四组患者的平均AT-III活性均无显著差异。在这320名接受雌激素替代疗法的患者中，未发生心肌梗死、中风或血栓栓塞性疾病。
